CAMBRIDGE, Mass., May 13 /PRNewswire/ -- Xennex, Inc. (Xennex) announced today a major leap for GeneCards(R) with the release of Version 3.0 beta, available at http://www.genecards.org/v3.
The new GeneCards Version 3.0 features a significantly upgraded infrastructure, including a comprehensive relational biological database, and a novel, sophisticated and speedier search engine. It provides capabilities for highly effective and well-targeted queries, a user-friendly display and clear data navigation. Also released is a preliminary version of GeneDecks Version 3, which makes use of the new GeneCards relational database for complex analyses on sets of genes.
Dr. David Warshawsky, President and CEO of Xennex, stated: "We are delighted to see the outstanding progress resulting from our partnership with the GeneCards team at the Weizmann Institute of Science. GeneCards Version 3.0 is a major milestone that will enable users around the world to better perform cutting-edge research in various fields of biology and medicine, and in the discovery and development of diagnostics and therapeutics."
Xennex is providing its commercial users with access to the new GeneCards Version 3.0 beta relational database. With GeneCards Version 3.0, Xennex' customers will be able to integrate GeneCards data into their internal systems, and perform comprehensive data mining.
GeneCards(R) (http://www.genecards.org/) is a searchable, integrated database of human genes that provides concise genomic, transcriptomic, genetic, proteomic, functional and disease-related information on all known and predicted human genes. Information is featured in 18 GeneCards sections and includes orthologies, disease relationships, mutations and SNPs, gene expression, gene function, pathways, protein-protein interactions, related drugs & compounds and direct links to valuable research reagents and tools such as antibodies, recombinant proteins, clones, expression assays and RNAi reagents. GeneCards was developed over the last 12 years by a world-leading bioinformatics team at the Weizmann Institute of Science in Israel, directed by Marilyn Safran and by Professor Doron Lancet of the Department of Molecular Genetics, Head of the Crown Human Genome Center, and the incumbent of the Ralph & Lois Silver Professorial Chair of Human Genomics at the Weizmann Institute of Science.
Founded in 2003, Xennex, Inc. (http://www.xennexinc.com) is a dynamic privately held company that is dedicated to providing Biotechnology, Pharmaceutical and other life sciences companies, as well as organizations dealing with biotechnology intellectual property, the highest level of services and tools to enhance their gene-based research. Xennex' products help such organizations to optimize their efforts to develop innovative medical products and services. Xennex' customers include many of the world's leading biotech and pharmaceutical companies and organizations dealing with intellectual property, located in North America, Europe and Japan. Xennex' products are used in hundreds of commercial and academic organizations by tens of thousands of users around the globe.
This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.
CONTACT: David Warshawsky, Ph.D., Chief Executive Officer of Xennex, Inc.,
Web site: http://www.xennexinc.com/